Imugene Issues Addendum to Extraordinary General Meeting Notice

Imugene Limited ( (AU:IMU) ) has issued an announcement.

Imugene Limited has issued an addendum to its Notice of Extraordinary General Meeting, detailing amendments to the original notice and explanatory memorandum. The meeting is scheduled for June 26, 2025, and will be held both in-person and online. The addendum includes corrections to the exercise prices for a security code and provides guidance for shareholders on voting queries. This announcement ensures clarity and accuracy for shareholders ahead of the meeting, reflecting Imugene’s commitment to transparency and effective communication with its stakeholders.

The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.

More about Imugene Limited

Imugene Limited is a clinical stage immuno-oncology company focused on developing novel immunotherapies designed to activate the immune system of cancer patients to treat and eradicate tumors. The company’s pipeline includes an off-the-shelf cell therapy CAR T drug targeting CD19 for blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy aimed at treating various cancers in combination with standard care drugs and emerging immunotherapies.

Average Trading Volume: 23,805,993

Technical Sentiment Signal: Sell

Current Market Cap: A$126.9M

See more insights into IMU stock on TipRanks’ Stock Analysis page.